The girl ran up to the old woman, took the basket from her2 and said, "Old granny, let me go with you to your son's home."
这个小女孩跑到老奶奶跟前，接过篮子说：“老奶奶，让我送你到你儿子家去吧。”
A breakthrough came more than a decade ago when Genentech, a Californian biotech firm, launched a drug that attacks breast-cancer cells with too much of a certain protein, HER2.
十多年前就取得了重大进展，一个加州的生物科技公司Genentech(中文名：基因泰克)发行了一种药物，这种药物攻击蛋白质HER2(中文名：人表皮生长因子受体- 2)含量过多的乳腺癌细胞。
The SPOT-Light test can measure how many HER2 genes are present in a sample of breast tumor; the more genes there are, the more likely the tumor will respond to treatment with Herceptin.
SPOT - Light检测可计算出一个乳腺癌样本中存在多少her 2基因；这种基因越多，用赫赛汀治疗肿瘤就越有效。
The HER2 gene regulates the growth of cancer cells.
HER2基因可以调节肿瘤细胞的生长速度。
This helps to stop the growth of HER2 cancer cells.
这个可以有助于阻止HER2所致的肿瘤细胞的生长。
Methods: Immunohistochemistry was used to detect HER2 expression in 110 cases of breast carcinoma.
方法：应用免疫组织化学方法，检测110例乳腺癌组织中her 2蛋白表达，结合随访资料分析。
Expression of HER2 is associated with clinicopathological features in the gastroesophageal cancer.
HER2在胃食管结合部癌中的表达与临床病理特征关系密切。
In HER2-positive breast cancer, stimulation of the HER2 receptor contributes to cancer cell growth.
在HER 2阳性的乳腺癌患者中，HER2受体受到刺激后也能促进癌细胞增长。
The new drug is targeted to treat breast cancers that carry a special genetic marker, known as HER2.
这种新药是用于治疗乳腺癌，这种携带了表皮生长因子受体2（Her-2）的特异生物标记的疾病。
The researchers then looked at the drug Herceptin, which is used to treat HER2-positive breast cancer.
研究者们研究被用来治疗HER2阳性乳腺癌症的药物赫赛汀。
A three-dimensional pharmacophore model of two types of HER2 inhibitors was obtained by using the CATALYST software.
通过CATALYST软件包得到了两类HER2抑制的三维药效团模型。
HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer.
HER2的异质性会影响HER 2阳性转移性乳腺癌患者曲妥珠单抗的效果和生存期。
HER2 is a protein involved in normal cell growth. It is found on some types of cancer cells, including breast cancer cells.
HER2是维持细胞正常生长的一种蛋白质，也存在于某些癌细胞，如乳腺癌。
Perhaps the most famous of all targeted therapeutics is Genentech's (NYSE: DNA) Herceptin, which inhibits the HER2 receptor.
所有靶向治疗中最负盛名的可能就是基因泰克（Genentech）的Herceptin，该药可抑制HER2受体。
Methods The expression of HER2, MMP2, MMP9 was detected by immunohistochemical staining in 114 specimens of breast cancer patients.
方法采用免疫组织化学的方法对114例乳腺癌组织标本中HER2、MMP 2、MMP 9的表达情况进行检测。
A total of 210 women with early breast cancer who tested positive for human epidermal growth factor receptor 2 (HER2) were enrolled.
共有210名患有人表皮生长因子受体2 (HER2)阳性的早期乳腺癌的女性患者参加了实验。
Tykerb works by depriving tumor cells of signals needed to grow. Tykerb enters the cell and blocks the function of the HER2 protein.
拉帕替尼能阻断肿瘤细胞生长的信号，进入细胞后能阻止HER2蛋白发挥作用。
Triple-negative breast cancers are breast cancers that have tested negative for estrogen receptors, progesterone receptors and HER2.
三阴性乳腺癌是雌激素受体、孕酮受体和HER2检测皆为阴性的乳腺癌。
Further, the drug Herceptin, which is used to treat HER2-positive breast cancer, was found to target and destroy the cancer stem cells.
此外，发现用于治疗HER 2阳性乳腺癌的药物赫赛汀，能够靶向和摧毁癌症干细胞。
Objective To study the feasibility of adenoviral transduction of Herceptin complete antibody gene and its effect on Her2 over expressing cancer.
目的探讨应用基因治疗方法表达完全抗体的可行性及其对肿瘤的治疗作用。
The FDA approval of Tykerb was based on the results of a study involving approximately 400 breast cancer patients with advanced-stage HER2 disease.
FDA参照大约400例晚期her 2阳性的乳腺癌病例的研究结果的基础上，批准了拉帕替尼应用于临床。
According to the FDA, Tykerb inhibits tumor growth by going inside cells containing the HER2 protein and blocking signals that promote tumor growth.
根据FDA提供的资料，拉帕替尼通过进入表达HER2蛋白的细胞，阻滞促进肿瘤生长的信号。
In estrogen receptor (er) -negative tumors, AR was distinctively associated with human epidermal growth factor receptor type 2 (HER2) overexpression.
雌激素受体(ER)阴性的肿瘤，AR明显与人表皮生长因子受体2型(her2)的过度表达相关。
Objective To analyse the clinical and pathological Characteristics of HER2 expression and observe prognostic significance of HER-2 in breast cancer .
目的：分析HER2表达的临床意义及病理特征，观察HER2表达对乳腺癌预后的影响。
Expression of HER2 in breast cancer tissues was examined by immunohistochemistry, and serum HER2 level in breast cancer patients was examined by ELISA.
应用免疫组织化学方法检测乳腺癌组织her2的表达，ELISA法检测血清her2的表达水平。
Trastuzumab is a humanised antibody, designed to target and block the function of HER2, a protein produced by a specific gene with cancer-causing potential.
曲妥珠单抗是一种人源化抗体，用于靶向和阻断her2的功能，而后者是由特异基因编码的一种蛋白，具有致癌潜能。
We investigated the impact of HER2 heterogeneity on trastuzumab responses and clinical outcomes in 112 patients with HER2-positive metastatic breast cancer.
我们调查了HER 2异质性对112例her 2阳性转移性乳腺癌患者的曲妥珠单抗疗效和临床预后的影响。
We investigated the impact of HER2 heterogeneity on trastuzumab responses and clinical outcomes in 112 patients with HER2-positive metastatic breast cancer.
我们调查了HER 2异质性对112例her 2阳性转移性乳腺癌患者的曲妥珠单抗疗效和临床预后的影响。
应用推荐